Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on LNTH stock, giving a Buy rating on January 23.
Anthony Petrone’s Buy rating for Lantheus Holdings (ticker LNTH) can be attributed to several observations regarding the company’s recent CEO transition and ongoing business strategy. Despite the unexpected timing of the CEO change following a significant drop in stock price post Phase 3 SPLASH study results, the transition appears to have been part of a well-considered plan. It is not seen as an abrupt reaction to recent developments but rather a strategic move that had been contemplated over time. This suggests that the company’s leadership changes were not a direct consequence of the trial’s outcomes but part of an ongoing annual review process, indicating stability in the company’s governance.
Furthermore, the appointment of Brian Markison, a seasoned member of the Board since 2012, as the new CEO underscores a high degree of leadership continuity and implies that the company’s strategic direction, particularly its focus on “Theranostics,” will remain consistent. With Markison’s strong background in pharmaceuticals, it is anticipated that Lantheus may place an increased emphasis on expanding its therapeutic assets, potentially through mergers and acquisitions, which could enhance the company’s growth prospects and justify the Buy rating.
According to TipRanks, Petrone is a 3-star analyst with an average return of 2.1% and a 47.70% success rate. Petrone covers the Healthcare sector, focusing on stocks such as Lantheus, ADMA Biologics, and Boston Scientific.
In another report released on January 23, JMP Securities also reiterated a Buy rating on the stock with a $100.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Lantheus (LNTH) Company Description:
Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.
Read More on LNTH:
- Lantheus Announces CEO Retirement and Successor Appointment
- Lantheus Announces CEO Succession Plan
- Lantheus reaffirms 2023 revenue view $1.295B-$1.297B, consensus $1.28B
- Lantheus CEO Mary Anne Heino to retire, Brian Markison to succeed
- Lantheus announces acceptance of its first-to-file ANDA for generic LUTATHERA
